Files in this item

FilesDescriptionFormat

application/pdf

application/pdfSSRN-id3093610.pdf (475kB)
(no description provided)PDF

Description

Title:CRISPR, Patents, and the Public Health
Author(s):Sherkow, Jacob S.
Subject(s):crispr
patents
public health
gene editing
drug pricing
insurance
research
regulation
law
policy
Abstract:Patent issues surrounding CRISPR, the revolutionary genetic editing technology, may have important implications for the public health. Patents maintain high prices for novel therapies, limiting patient access. Relatedly, insurance coverage for expensive therapies is waning. Patents also misallocate research and development resources to profitable disease indications rather than those that necessarily impinge on the public health. And it is unclear how CRISPR therapies will figure into the current regulatory framework for biosimilars. Policy makers and physicians should consider these issues now, before CRISPR therapies become widely adopted—and entrenched—in the marketplace.
Issue Date:2017-12-17
Publisher:Yale Journal of Biology & Medicine
Citation Info:Jacob S. Sherkow, CRISPR, Patents, and the Public Health, 90 Yale J. Biol. & Med. 667 (2017)
Genre:Article
Type:Text
Language:English
URI:http://hdl.handle.net/2142/110379
Date Available in IDEALS:2021-09-07


This item appears in the following Collection(s)

  • Illinois Research and Scholarship
    This is the default collection for all research and scholarship developed by faculty, staff, or students at the University of Illinois at Urbana-Champaign

Item Statistics